BRC, although classified into five well-defined subtypes (Luminal A, Luminal B, HER2+, HER2-enriched, and Basal-Like (Triple-Negative)), are extremely heterogeneous in terms of gene mutations and aberrant expression of molecules linked to tumor progression, with LINC01133 being a target of great interest, considering the dual actions it may exhibit in different subtypes and classes of each subtype. Here, ERBB2 is linked to neoplasm.